TY - JOUR
T1 - Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia
AU - Aoki, Jun
AU - Kanamori, Heiwa
AU - Tanaka, Masatsugu
AU - Yamasaki, Satoshi
AU - Fukuda, Takahiro
AU - Ogawa, Hiroyasu
AU - Iwato, Koji
AU - Ohashi, Kazuteru
AU - Okumura, Hirokazu
AU - Onizuka, Makoto
AU - Maesako, Yoshitomo
AU - Teshima, Takanori
AU - Kobayashi, Naoki
AU - Morishima, Yasuo
AU - Hirokawa, Makoto
AU - Atsuta, Yoshiko
AU - Yano, Shingo
AU - Takami, Akiyoshi
N1 - Publisher Copyright:
© 2016 Wiley Periodicals, Inc.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Previous studies have repeatedly reported that increasing age is a significant risk factor for worse outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) among patients with acute myeloid leukemia (AML). However, more recent studies reported conflicting results regarding the association between age and outcomes in elderly patients. Therefore, we conducted a large-scale, nationwide retrospective study to examine the impact of age on outcomes of allo-HSCT with reduced intensity conditioning (RIC) for AML patients who were older than 50 years. Of the 757 patients, 89 patients (11.8%) were 50-54, 249 patients (32.9%) were 55-59, 301 patients (39.8%) were 60-64 and 118 patients (15.6%) were ≥65 years old. The 3-year overall survival (OS) (47.8, 45.2, 37.9, and 36.6% for patients aged 50-54, 55-59, 60-64, and ≥65 years, respectively, P=0.24) and nonrelapse mortality (NRM) (24.0, 22.8, 29.2, and 27.6% for patients aged 50-54, 55-59, 60-64, and ≥65 years, respectively, P=0.49) were not significantly different among the four age groups. Multivariate analysis revealed that increased age had no significant effect on OS or NRM after adjusting for covariates. These results suggested that advanced patient age is not a contraindication for RIC allo-HSCT in elderly AML patients.
AB - Previous studies have repeatedly reported that increasing age is a significant risk factor for worse outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) among patients with acute myeloid leukemia (AML). However, more recent studies reported conflicting results regarding the association between age and outcomes in elderly patients. Therefore, we conducted a large-scale, nationwide retrospective study to examine the impact of age on outcomes of allo-HSCT with reduced intensity conditioning (RIC) for AML patients who were older than 50 years. Of the 757 patients, 89 patients (11.8%) were 50-54, 249 patients (32.9%) were 55-59, 301 patients (39.8%) were 60-64 and 118 patients (15.6%) were ≥65 years old. The 3-year overall survival (OS) (47.8, 45.2, 37.9, and 36.6% for patients aged 50-54, 55-59, 60-64, and ≥65 years, respectively, P=0.24) and nonrelapse mortality (NRM) (24.0, 22.8, 29.2, and 27.6% for patients aged 50-54, 55-59, 60-64, and ≥65 years, respectively, P=0.49) were not significantly different among the four age groups. Multivariate analysis revealed that increased age had no significant effect on OS or NRM after adjusting for covariates. These results suggested that advanced patient age is not a contraindication for RIC allo-HSCT in elderly AML patients.
UR - http://www.scopus.com/inward/record.url?scp=84959091957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959091957&partnerID=8YFLogxK
U2 - 10.1002/ajh.24270
DO - 10.1002/ajh.24270
M3 - Article
C2 - 26663096
AN - SCOPUS:84959091957
VL - 91
SP - 302
EP - 307
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 3
ER -